Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenstrom’s Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study

Christian Buske, MD, Alessandra Tedeschi, MD, Judith Trotman, MBChB, Ram´on Garcıa-Sanz, MD, PhD, David MacDonald, MD, Veronique Leblond, MD, PhD, Beatrice Mahe, MD, Charles Herbaux, MD, Jeffrey V. Matous, MD, Constantine S. Tam, MBBS, MD, Leonard T. Heffner, MD, Marzia Varettoni, MD, M. Lia Palomba, MD, Chaim Shustik, MD, Efstathios Kastritis, MD, Steven P. Treon, MD, PhD, Jerry Ping, PhD, Bernhard Hauns, MD, PhD, Israel Arango-Hisijara, MD, and Meletios A. Dimopoulos, MD

Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenstrom’s Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study

Accepted on August 26, 2021 and published at ascopubs.org/journal/jco on October 4, 2021: DOI https://doi.org/10.1200/JCO.21.00838